23andMe's founder Anne Wojcicki wins bid for DNA testing firm

Anne Wojcicki, through her non-profit TTAM Research Institute, has won a bankruptcy auction to regain control of 23andMe with a $305 million bid, surpassing Regeneron Pharmaceuticals' $256 million offer. The deal, expected to close after a June 17 court hearing, follows 23andMe's bankruptcy filing in March due to declining demand and a significant 2023 data breach, amid ongoing legal challenges from multiple states regarding customer data privacy.

Analysis

Anne Wojcicki, through her non-profit TTAM Research Institute, is poised to regain control of 23andMe with a successful $305 million bid in a bankruptcy auction, exceeding Regeneron Pharmaceuticals' $256 million offer. This acquisition follows 23andMe's Chapter 11 bankruptcy filing in March, which was precipitated by a significant decline in demand for its DNA-testing services and a major 2023 data breach that exposed sensitive genetic and personal information of millions of users. The transaction, expected to close after a court hearing scheduled for June 17, faces considerable scrutiny due to ongoing legal action from New York and over two dozen other U.S. states challenging the sale of customer private information. TTAM Research Institute has publicly committed to upholding 23andMe's existing privacy policies and adhering to all applicable data protection laws. Regeneron Pharmaceuticals had expressed willingness to make a new offer but requested a $10 million breakup fee if Wojcicki’s bid was ultimately accepted, indicating the perceived value in 23andMe's assets despite its challenges.

Key Decisions for Investors

• Investors in Regeneron Pharmaceuticals (REGN) should consider that while the company lost the bid for 23andMe, it avoids acquiring an entity burdened with significant data privacy litigation and reputational issues, though it forfeits a potential distressed asset acquisition and may incur costs related to the bidding process.
• The successful acquisition by an entity linked to 23andMe's founder, amidst severe data privacy concerns and active lawsuits, underscores the heightened operational and legal risks for companies in the genetic data sector; focus should be on how the new ownership will address these extensive liabilities and attempt to rebuild consumer trust.
• The court hearing scheduled for June 17 is a critical near-term catalyst, and its outcome, along with developments in the multi-state lawsuits, will significantly influence 23andMe's operational stability and the strategic direction under TTAM Research Institute's control.